SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to ...
Why Is COVID-19 Vaccine Maker Novavax Stock Trading Lower On Wednesday?
On November 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for ...
FiercePharma2d
Novavax coughs up $123.8M to settle COVID vaccine supply dispute with UK
Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...
TG Therapeutics: Strong Financial Performance and Strategic Expansion Drive Buy Rating
Analyst Mayank Mamtani of B.Riley Financial reiterated a Buy rating on TG Therapeutics (TGTX – Research Report), retaining the price ...
News Medical4d
Key FDA Decisions Made in 2024
Regulating drug discovery and pharmaceutical manufacturing, the FDA ensures the safety and effectiveness of innovative ...
Le Lézard5d
HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration
HG202 is the first CRISPR/Cas13Y RNA-targeting therapy to enter clinical development and the only clinical-stage CRISPR RNA-editing therapy for age-related macular degeneration Preclinical studies in ...